The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck)

Bioorg Med Chem Lett. 2006 Dec 1;16(23):5973-7. doi: 10.1016/j.bmcl.2006.08.132. Epub 2006 Sep 25.

Abstract

This communication details the synthesis, biological activity, and binding mode of a novel class of 2-benzimidazole substituted pyrimidines. The most potent analogs disclosed showed low nanomolar activity for the inhibition of Lck kinase and a representative analog was co-crystallized with Hck (a structurally related member of the Src family kinases).

MeSH terms

  • Benzimidazoles / chemistry*
  • Hydrogen Bonding
  • Inhibitory Concentration 50
  • Interleukin-2 / metabolism
  • Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / antagonists & inhibitors*
  • Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / chemical synthesis
  • Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / metabolism
  • Molecular Structure
  • Protein Kinase Inhibitors / chemical synthesis*
  • Protein Kinase Inhibitors / chemistry
  • Protein Kinase Inhibitors / pharmacology*
  • Proto-Oncogene Proteins c-hck / chemistry
  • Proto-Oncogene Proteins c-hck / metabolism
  • Pyrimidines / chemistry*
  • Structure-Activity Relationship

Substances

  • Benzimidazoles
  • Interleukin-2
  • Protein Kinase Inhibitors
  • Pyrimidines
  • benzimidazole
  • Lymphocyte Specific Protein Tyrosine Kinase p56(lck)
  • Proto-Oncogene Proteins c-hck
  • pyrimidine